Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a Three-Drug cocktail calm a suicidal crisis in days?

NCT ID NCT06133114

Disease control Sponsor: Icahn School of Medicine at Mount Sinai Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled This study
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 28, 2026 · Last updated Jul 29, 2026 · Updated 1 time

Summary

This trial tests whether giving a combination of clonazepam, olanzapine, and buprenorphine for just two days can quickly relieve the intense emotional distress of Suicide Crisis Syndrome in hospitalized adults. Participants are randomly assigned to receive one, two, or three of these medications, or standard care. The goal is to see if the drug pulses can reduce distress and suicidal thoughts by the time of discharge and one month later.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
clonazepam, olanzapine, and buprenorphine, alone or in combination
What this could lead to
If successful, this could point toward a fast-acting medication strategy to reduce acute emotional distress and suicide risk in hospitalized patients.
What could go wrong
This is a small early-phase trial, and the medications have side effects such as drowsiness, dizziness, and risk of dependence. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Started

Mar 2024

Finished

Mar 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient admitted to an inpatient unit and ruled in for SCS diagnosis using SCS-C * Willing to stay in the hospital voluntarily, if medically necessary, for at least 4 days after enrolling in the study. * Patient admitted to an inpatient unit as a result of a recent (i.e., past-month) suicide attempt, as defined by the C-SSRS (Columbia Suicide Rating Scale). * Admitted to an inpatient unit in the last 36 hrs. * Able to understand the nature and the substance of the consent form. * Currently domiciled. * Able and willing to provide verifiable contact information for follow-up. Exclusion Criteria: * Intellectual disability, cognitive impairment, or linguistic limitation precluding understanding of the consent or research questions. * Past adverse reactions to clonazepam, olanzapine, or buprenorphine * Past history of opiate or benzodiazepine use d/o in the last 2 years * On agonist therapy for opiate addiction * Ongoing treatment with clonazepam or olanzapine. * Significant medical or neurological disease or possible delirium that might interfere with study participation or capacity to provide informed consent. * Receiving involuntary treatment in psychiatric unit * Clinical suspicion of malingering by a CP. * Undomiciled.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Psychological distress are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Psychological distress Suicide crisis syndrome

Contacts and locations

Locations

  • Icahn School of Medicine at Mount Sinai

    New York, New York, 10029, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.